Quinoline compounds

• US 5,650,415 A
• Filed: 06/07/1995
• Issued: 07/22/1997
• Est. Priority Date: 06/07/1995
• Status: Expired due to Fees

• Current Assignee: Sugen Incorporated (Pharmacia Corp.)
• Original Assignee: Sugen Incorporated (Pharmacia Corp.)
• Inventors: Tang, Peng Cho, Sun, Li, McMahon, Gerald
• Primary Examiner(s): Rotman, Alan L.
• Assistant Examiner(s): SMITH, LYMAN
• Application Number:
  US08/487,090
• Time in Patent Office: 776 Days
• Field of Search: 546/153, 546/159, 514/312, 514/313
• US Class Current: 514/312
• CPC Class Codes: A61K 31/47 Quinolines; Isoquinolines
• CPC Class Codes: A61K 31/4706 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
• CPC Class Codes: C07D 215/54 attached in position 3

Abstract

A method of inhibiting cell proliferation or differentiation by exposing a cell to a compound of the formula ##STR1## or a pharmaceutically acceptable salt thereof. Q is selected from the group consisting of NH and S, n is 0 or 1; and R_1-9 are independently selected from the group consisting of halo, trihalomethyl, alkyl, nitro, hydroxy, alkoxy, sulphoxy, sulphonyl, amide, sulfonamide, carboxamide, amino, and hydrogen. Also provided is a compound of the structure ##STR2##

Claims

1. A compound of the structure ##STR6## or a pharmaceutically acceptable salt thereof.

2. A method of inhibiting cell proliferation or differentiation comprising exposing a cell to a compound of the formula:

##STR7## or a pharmaceutically acceptable salt thereof, wherein Q is selected from the group consisting of NH and S,

n is 0 or 1; and

R_1-9 are independently selected from the group consisting of halo, trihalomethyl, alkyl, nitro, hydroxy, alkoxy, sulphoxy, sulphonyl, amide, sulfonamide, carboxamide, amino, and hydrogen.

3. The method of claim 2 wherein said cell proliferation or differentiation is associated with a cell proliferation or cellular differentiation disorder selected from the group consisting of HER2 disorders, EGFR disorders, IGFR disorders, PDGFR disorders, met disorders, Src disorders, and KDR/FLK-1 disorders.

4. The method of claim 2, wherein Q is NH.

5. The method of claim 2, wherein Q is S.

6. The method of claim 2, wherein n is 0.

7. The method of claim 2, wherein n is 1.

8. The method of claim 2, wherein said disorder is a HER2 disorder.

9. The method of claim 2, wherein said disorder is an EGFR disorder.

10. The method of claim 2, wherein said disorder is an FGFR disorder.

11. The method of claim 2, wherein said disorder is a PDGFR disorder.

12. The method of claim 2, wherein said disorder is a met disorder.

13. The method of claim 2, wherein said disorder is a Src disorder.

14. The method of claim 2, wherein said disorder is a KDR/FLK-1 disorder.